Dr. Rosenberg on Immunotherapy in Non-Metastatic Muscle Invasive Bladder Cancer

Jonathan E. Rosenberg, MD
Published: Thursday, Aug 03, 2017



Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses immunotherapy in non-metastatic muscle-invasive bladder cancer.

Immunotherapy for this patient population is in an experimental stage, says Rosenberg.

Ongoing phase III trials are focusing on adjuvant therapy, which Rosenberg says patients who cannot receive platinum-based therapy after surgery should consider.
 


Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses immunotherapy in non-metastatic muscle-invasive bladder cancer.

Immunotherapy for this patient population is in an experimental stage, says Rosenberg.

Ongoing phase III trials are focusing on adjuvant therapy, which Rosenberg says patients who cannot receive platinum-based therapy after surgery should consider.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x